

03 Jul 2022 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: a look at top executive compensation; BioMarin preps for Roctavian's EU debut; Argenx eyes launch hat-trick for Vyvgart; is a biopharma M&A wave coming; and J&J's Gorsky offers leadership lessons.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 1 July 2022, including: a look at top executive compensation; [\*BioMarin Pharmaceutical Inc.\*](#) preps for Roctavian's EU debut; [\*argenx N.V.\*](#) eyes launch hat-trick for Vyvgart; is a biopharma M&A wave coming; and [\*Johnson & Johnson\*](#)'s Gorsky offers leadership lessons.

This and all our other podcasts are available on the Pharma Intelligence channel on [\*Apple Podcasts\*](#), [\*Google Podcasts\*](#), [\*SoundCloud\*](#), [\*TuneIn\*](#) and [\*Spotify Podcasts\*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[\*Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again\*](#)" - Scrip, 28 Jun, 2022.)

(Also see "[\*BioMarin Rolls Up Sleeves To Prepare For Roctavian's EU Debut\*](#)" - Scrip, 24 Jun, 2022.)

(Also see "[\*Argenx Eyes Hat-Trick Of Successful Launches For Vyvgart After CHMP Thumbs-Up\*](#)" - Scrip, 24 Jun, 2022.)

(Also see "[\*Are Market Conditions Setting Up A Biopharma M&A Wave?\*](#)" - Scrip, 23 Jun, 2022.)

(Also see "[\*I&J's Gorsky Offers Leadership Lessons As He Gets Set To Advise Apple\*](#)" - Scrip, 30 Jun, 2022.)

[Click here to explore this interactive content online](#) ✨